Skip to content

Real-world effectiveness and safety of intranasal esketamine for treatment-resistant depression: data from the enTRD registry

Maximilian Preiß, Valentin Popper, Luna Helene Charlotte Faber, Tg Baumgartner, Philip Miguel Baberis-Martinez, Edda Pjrek, Gregor Gryglewski, Lucie Bartova, Siegfried Kasper, Dan Rujescu, Lukas Pezawas

European Psychiatry June 23, 2026 DOI: 10.1192/j.eurpsy.2026.12234 (opens in new tab)

Read Full Text
Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Observational Peer reviewed
Population Patients with TRD from the enTRD registry
Topics Depression Esketamine
Keywords Nasal administration Action physics Onset of action Adverse effect Anesthesia Intensive care medicine
Key findings Real-world data from the enTRD registry show effectiveness and safety of intranasal esketamine for TRD.

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Comparable studies

Other observational and cohort studies on esketamine for depression, most cited first.

Study Year Design Participants
Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment‐resistant depression Patients with treatment-resistant bipolar depression (B-TRD) and unipolar... 2023 Observational cohort n = 70
Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study. Adults with treatment-resistant depression 2023 Observational study n = 62
Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING) Treatment-resistant depression patients 2023 Retrospective, multicentric, real-world study n = 149
Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study Patients with treatment-resistant depression and a substance use disorder 2023 Observational, retrospective, multicentre study n = 26
Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review Patients with treatment-resistant depression and bipolar depression meeting DSM-IV-TR... 2017 Retrospective observational study n = 27

Related reading

Explore topics

Depression Esketamine

By condition and practice

Esketamine for depression Ketamine for depression